MIRADON Drug Patent Profile
✉ Email this page to a colleague
When do Miradon patents expire, and when can generic versions of Miradon launch?
Miradon is a drug marketed by Schering and is included in one NDA.
The generic ingredient in MIRADON is anisindione. Additional details are available on the anisindione profile page.
Summary for MIRADON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Patent Applications: | 1,518 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MIRADON at DailyMed |
US Patents and Regulatory Information for MIRADON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | MIRADON | anisindione | TABLET;ORAL | 010909-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |